Array BioPharma (NASDAQ:ARRY) Has Target Of $33 Give by Equity Research Analysts at Wells Fargo. “Outperform” Didn’t change.

June 29, 2018 - By Carey Conley

Array BioPharma Inc. (NASDAQ:ARRY) Corporate Logo

Big Money Sentiment increased to 1.74 in 2018 Q1. It has change of 0.44, from 2017Q4’s 1.3. The ratio is positive due to Array BioPharma Inc. positioning: 16 sold and 54 reduced. 55 funds amassed positions and 67 increased positions. Investors holded 194.11 million in 2017Q4 but now own 189.71 million shares or 2.27% less.

Clarivest Asset Management Ltd owns 200,581 shs. Rhumbline Advisers holds 0.01% or 193,778 shs. Schwab Charles Inv Management Incorporated accumulated 1.05M shs. California State Teachers Retirement reported 303,200 shs stake. Fny Managed Accounts Ltd Liability Com accumulated 174 shs. Hudson Bay Mngmt Limited Partnership has invested 0.02% of its capital in Array BioPharma Inc. (NASDAQ:ARRY). New York State Common Retirement Fund holds 260,616 shs or 0.01% of its capital. Ecor1 Capital Limited Liability has invested 4.99% of its capital in Array BioPharma Inc. (NASDAQ:ARRY). Bvf Il holds 5.06 million shs. Parametric Assocs Limited Liability Com accumulated 207,628 shs. Baker Bros Limited Partnership stated it has 5.66 million shs. Driehaus Ltd Limited Liability Company invested 1.55% in Array BioPharma Inc. (NASDAQ:ARRY). Weiss Multi invested 0.07% in Array BioPharma Inc. (NASDAQ:ARRY). Prelude Capital Ltd Liability Corp invested in 0.05% or 46,252 shs. The Vermont-based Birchview Capital Lp has invested 1.2% in Array BioPharma Inc. (NASDAQ:ARRY).

Array BioPharma Inc. had 11 insider sales and 0 insider purchases since January 16, 2018. This’s net activity of $6.95 million. Sandor Victor had sold 77,576 shs worth $1.46M. On Tuesday, January 16 the insider Haddock Jason sold $102,975.

Reiterated Array BioPharma (NASDAQ:ARRY) Rating.

On 28 June Wells Fargo have a $33 TP on Array BioPharma (NASDAQ:ARRY). A upside potential of 98.08 % have this TP. The $3.51 billion MC company have “Outperform” stock rating revealed to clients and investors in a research note.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Coverage

A total of 7 analysts rate Array Biopharma (NASDAQ:ARRY) as follows: 7 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:ARRY) has 13 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Monday, January 22 Leerink Swann upgraded Array BioPharma Inc. (NASDAQ:ARRY) to “Outperform” rating. On Tuesday, February 6 Stifel Nicolaus maintained Array BioPharma Inc. (NASDAQ:ARRY) rating. Stifel Nicolaus has “Buy” rating and $23.0 target. On Thursday, May 10 the stock of Array BioPharma Inc. (NASDAQ:ARRY) has “Buy” rating given by Cowen & Co. On Wednesday, February 7 the firm has “Outperform” rating by Leerink Swann given. On Wednesday, February 7 the stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Buy” rating by Cowen & Co. On Sunday, January 21 Stifel Nicolaus maintained Array BioPharma Inc. (NASDAQ:ARRY) with “Buy” rating. On Monday, June 25 the company was maintained by Piper Jaffray. On Tuesday, June 5 Cowen & Co maintained Array BioPharma Inc. (NASDAQ:ARRY) with “Buy” rating. In Tuesday, February 6 report Piper Jaffray maintained it with “Buy” rating and $21.0 target. On Thursday, June 28 the firm earned “Outperform” rating by Wells Fargo.

Ticker’s shares touched $16.66 during the last trading session after 1.42% change.Array BioPharma Inc. has volume of 1.40 million shares. Since June 29, 2017 ARRY has risen 92.14% and is uptrending. ARRY outperformed the S&P500 by 79.57%.

Investors wait Array BioPharma Inc. (NASDAQ:ARRY)’s quarterly earnings on August, 8., Zacks reports. Analysts forecast $-0.25 earnings per share, which is $0.08 down or 47.06 % from 2017’s $-0.17 earnings per share. 127.27 % negative EPS growth is what Wall Street’s forecasts after $-0.11 reported EPS last quarter.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.The firm is valued at $3.51 billion. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus.Currently it has negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

For more Array BioPharma Inc. (NASDAQ:ARRY) news announced briefly go to: Benzinga.com, Seekingalpha.com, Nasdaq.com, Benzinga.com or Fool.com. The titles are as follows: “Jordyn Fantuzzi” announced on June 28, 2018, “Key events next week – healthcare” on June 21, 2018, “3 Biotechs With Huge FDA Decisions in June” with a publish date: May 31, 2018, “Piper Jaffray, Stifel Defend Array Biopharma As Stock Falls On Profit-Taking” and the last “George Soros Bought This Clinical-Stage Biotech Stock. Should You?” with publication date: May 31, 2018.

Array BioPharma Inc. (NASDAQ:ARRY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.